Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, a clinical-stage biotechnology firm focused on immuno-neurology, announced its participation in two investor conferences. Firstly, at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, where management will be part of a panel at 10:30 a.m. ET. Secondly, they will engage in a fireside chat during the Stifel 2023 CNS Days virtually on March 28, 2023, at 12:00 p.m. ET. Webcasts for both events will be available on Alector's website, with replays accessible for 30 and 90 days respectively.
Alector is dedicated to developing therapies for neurodegenerative diseases, targeting immune dysfunction linked to conditions like Alzheimer’s and frontotemporal dementia.
Alector, a clinical-stage biotechnology firm, reported its financial results for Q4 and full year 2022, highlighting a cash position of $712.9 million sufficient to fund operations through 2025. The company is nearing completion of enrollment in the INVOKE-2 Phase 2 trial for AL002 in early Alzheimer’s disease, with data expected by Q4 2024. Collaboration revenue for 2022 was $133.6 million, down from $207.1 million in 2021, primarily due to prior year's income from the GSK agreement. R&D expenses rose to $210.4 million in 2022. Alector anticipates collaboration revenue between $15 million and $25 million for 2023.
Alector, Inc. (Nasdaq: ALEC) announced on December 6, 2022, that it granted stock options and restricted stock units (RSUs) to eight new employees. The awards included options to purchase 91,851 shares of common stock at an exercise price of $9.27 per share and RSUs for 40,961 shares. These grants are part of Alector’s 2022 Inducement Equity Incentive Plan. The stock options will vest over four years, while the RSUs will vest over three years.
Alector, Inc. (Nasdaq: ALEC) reported positive safety and biomarker data from its first-in-human Phase 1 study of AL101, aimed at increasing progranulin (PGRN) levels for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Conducted with 88 healthy volunteers, the trial demonstrated the drug's tolerability and ability to elevate PGRN in cerebrospinal fluid. Notably, multiple doses raised plasma PGRN levels to 160-200% above baseline. This data supports further exploration of AL101 for chronic conditions.
Alector, Inc. (NASDAQ: ALEC) reported its Q3 2022 financial results, revealing a significant decline in collaboration revenue to $14.9 million from $182.4 million YoY. The company continues to advance its clinical-stage pipeline, with ongoing enrollment in pivotal studies for latozinemab (AL001) and AL002 for Alzheimer’s disease, and has initiated a Phase 1 trial for AL044, targeting a key risk factor for the condition. With $758.3 million in cash and equivalents, Alector has sufficient runway through 2024 to support its ongoing research and development initiatives.
Alector, a clinical-stage biotechnology company based in South San Francisco, reported participation in two upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 3:20 p.m. ET, and the Stifel 2022 Healthcare Conference on November 16, 2022, at 8:00 a.m. ET. Both presentations will be available via webcast on Alector's website, with replays accessible for 90 days post-event. Alector focuses on immuno-neurology and innate immuno-oncology, targeting neurodegenerative diseases through innovative therapeutic approaches.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm, announced on November 1, 2022, the grant of stock options and restricted stock units (RSUs) to five new employees under its 2022 Inducement Equity Incentive Plan. A total of 202,080 stock options and 101,039 RSUs were awarded, with an exercise price of $9.29 per share. The options vest over four years, while RSUs vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment, reflecting Alector's commitment to enhancing its workforce in immuno-neurology and immuno-oncology.
Alector (Nasdaq: ALEC) has promoted Clare Hunt to Chief People Officer, enhancing its commitment to employee culture and development. Since 2017, Hunt has contributed to a workforce growth of 44%, now exceeding 270 employees, with notable representation of women in leadership (50%) and R&D (64%). Alector has received the Great Place to Work® certification for three consecutive years and was listed in Fortune's “Best Workplaces in Biopharma” for the second year. This promotion reflects Alector's strategy to align talent acquisition with its growth objectives.
Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on immuno-neurology, has granted stock options and restricted stock units (RSUs) to six new employees. The awards include options for 103,462 shares at an exercise price of $9.46, matching the closing price on September 30, 2022. These options have a ten-year term and will vest over four years, while RSUs will vest over three years. This compensation is part of the 2022 Inducement Equity Incentive Plan and aims to attract talent critical to Alector’s innovative work in treating neurodegenerative diseases.
Alector, Inc. (Nasdaq: ALEC) has initiated a Phase 1 clinical trial for AL044, its first-in-class drug candidate targeting the MS4A gene, a significant genetic risk factor for Alzheimer’s disease (AD). The trial will evaluate the safety, pharmacokinetics, and target engagement of AL044 in approximately 72 healthy participants. AL044 aims to modulate microglia to address multiple AD pathologies. Alector's approach represents a novel strategy to treat neurodegeneration, contrasting with existing therapies. The company is also advancing two additional drug candidates for AD.